Future potential of thymidylate synthase inhibitors in cancer therapy

Bibliography

• CARRERAS CW, SANTI DV: The catalytic mechanism and structure of thymidylate synthase. Ann. Rev Biochem. (1995) 64:721–762.
   PubMed Web of Science ®Google Scholar
• NEVINS JR: E2F: a link between the Rb tumor suppressor protein and viral oncoproteins. Science (1992) 258:424–429.
   PubMed Web of Science ®Google Scholar
• FARBER S, DIAMOND LK, MERCER RD et al.: Temporary remissions in acute leukemia in children produced by folic acid antagonist, 4-aminopteroyl-glutamic acid (aminopterin). N Engl. Med. (1948) 238:787–793.
   PubMed Web of Science ®Google Scholar
• BURCHENAL FH, KARNOFSKY DA, SOUTHAM CM et al: Clinical experience with the 4-amino derivatives of pteroylglutamic acid and 2,6-diaminopurine in the treatment of neoplastic disease. Am. Med. (1949) 7:420.
   Web of Science ®Google Scholar
• ALLEGRA CJ, CHABNER BA, DRAKE JC, LUTZ R, RODBARD D, JOLIVET J: Enhanced inhibition of thymidylate synthase by methotrexate polyglutamates. Biol. Chem. (1985) 26:9720–9726.
   Google Scholar
• ALLEGRA CJ, DRAKE JC, JOLIVET J, CHABNER BA: Inhibition of phosphoribosylaminoimidazolecarboxamide transformylase by methotrexate and dihydrofolic acid polyglutamates. Proc. Nat. Acad. Sci. USA (1985) 82:4881–4885.
   PubMed Web of Science ®Google Scholar
• HERTZ R, LEWIS J Jr, LIPSETT MB: Five years experience with the chemotherapy of metastatic choriocarcinoma and related trophoblsatic tumors in women. Amer..). Obstet. Cynec. (1961) 82:631–640.
   PubMed Web of Science ®Google Scholar
• KAMEN BA, COLE PD, BERTINO JR: Folate antagonists. In: Cancer Medicine (5th edn). Kufe DW, Pollock RE, Weichel RR et al. (Eds), BC Decker, Inc., Hamilton, Ontario, Canada (2000).
   Google Scholar
• FEAGAN BJ, ROCHON J, FED ORAK RN et al.: Methotrexate for the treatment of Crohn's disease. N Engl. I Med. (1995) 332:292–297.
   PubMed Web of Science ®Google Scholar
• BORSA J, WHITMORE GF: Cell killingstudies on the mode of action of methotrexate on L-cells in vitro. Cancer Res. (1969) 29:737–744.
   PubMed Web of Science ®Google Scholar
• •Classic study.
   Google Scholar
• COHEN SS: On the nature of thyminelessdeath. Ann. NY Acad. Sci. (1971) 186:292–301.
   PubMedGoogle Scholar
• CURTIN NJ, HARRIS AL, AHERNE GW: Mechanism of cell death following thymidylate synthase inhibition: 2'-deoxyuridine-5'-triphosphate accumulation, DNA damage, and growth inhibition following exposure to CB3717 and dipyridamole. Cancer Res. (1991) 51:2346–2352.
   PubMed Web of Science ®Google Scholar
• KWOK JB, TATTERSALL MH: Inhibition of
   Google Scholar
• -desamino- 2-methyl- 10-propagy1-5, 8-dide azafolic acid cytotoxicity by
   Google Scholar
• 10-dideazatetrahydrofolate in L1210 cells with decrease in DNA fragmentation and deoxyadenosine triphosphate pools. Biochem. Pharmacol (1991) 42:507–513.
   PubMed Web of Science ®Google Scholar
• SMITH SG, LEHMAN NL, MORAN RG: Cytotoxicity of antifolate inhibitors of thymidylate and purine synthesis to WiDr colonic carcinoma cells. Cancer Res. (1993) 53:5697–5706.
   PubMed Web of Science ®Google Scholar
• HOUGHTON JA, HARWOOD FG, TILLMAN DM: Thymineless death in colon carcinoma cells is mediated via Fas signalling. Proc. Nati Acad. Sci. USA (1997) 94:8144–8149.
   PubMed Web of Science ®Google Scholar
• HEIDELBERGER C, CHAUDHURI NK, DANNEBERG P et al.: Fluorinated pyrimidines, a new class of tumour-inhibitory compounds. Nature (1957) 179:663–666.
   PubMed Web of Science ®Google Scholar
• DANENBERG PV, DANENBERG KD: Effect of 5, 10-methylenetetrahydrofolate on the dissociation of 5-fluoro-2 '-deoxyuridylate from thymidylate synthetase: evidence for an ordered mechanism. Biochemistry (1978) 17:4018–4022.
   PubMed Web of Science ®Google Scholar
• ••Important biochemical studydemonstrating the TS ternary complex.
   Google Scholar
• GLAZER R, HARTMAN K: The effect of 5-fluorouracil on the synthesis and methylation of low molecular weight nuclear RNA in L1210 cells. Ma Pharmacol (1980) 17:245–249.
   PubMed Web of Science ®Google Scholar
• LENZ HJ, MANNO DJ, DANENBERG KD, DANENBERG PV: Incorporation of 5-fluorouracil into U2 and U6 SN3RNA inhibits mRNA precursor splicing. .1 Biol. Chem. (1994) 269:31962–31968.
   PubMed Web of Science ®Google Scholar
• SIERAKOWSKA H, SHUKLA RR, DOMINSKI Z, KOLE R Inhibition of pre-mRNA splicing by 5-fluoro-, 5-chloro-, and 5-bromouridine. Biol. Chem. (1989) 264:19185–19191.
   Web of Science ®Google Scholar
• KANAMARU R, KAKUTA H, SATO T, ISHIOKA C, WAKUI A: The inhibitory effects of 5-fluorouracil on the metabolism of preribosomal and ribosomal RNA in L1210 cells in vitro. Cancer Chemother: Pharmacol (1986) 17:43–46.
   PubMed Web of Science ®Google Scholar
• DOLNICK BJ, PINK JJ: Effects of 5-fluorouracil on dihydrofolate reductase and dihydrofolate reductase mRNA from methotrexate-resistant KB cells. J. Biol. Chem. (1985) 260:3006–3014.
   PubMed Web of Science ®Google Scholar
• GHOSHAL K, JACOB ST: An alternative molecular mechanism of action of 5-fluorouracil, a potent anticancer drug. Biochem. Pharmacol (1997) 53:1569–1575.
   PubMed Web of Science ®Google Scholar
• SCHMITTGEN TD, DANENBERG KD, HORIKOSHI T, LENZ HJ, DANENBERG PV: Effect of 5-fluoro- and 5-bromouracil substitution on the translation of human thymidylate synthase mRNA. I Biol. Chem. (1994) 269:16269–16275.
   Web of Science ®Google Scholar
• LONN U, LONN S: Interaction between 5-fluorouracil and DNA of human colon adenocarcinoma. Cancer Res. (1984) 44:3414–3418.
   PubMed Web of Science ®Google Scholar
• JOHNSTON PG, BEHAN KA, ALLEGRA CJ, DRAKE JC: Fluorouracil: active in ZD1694 (Tomudex)-resistant cell lines with markedly elevated thymidylate synthase levels. Natl. Cancer Inst. (1995) 87:1558–1559.
   Google Scholar
• PIZZORNO G, HANDSCHUMACHER RE, CHENG YC: Pyrimidine and purine antimetabolites. In: Holland-Frei Cancer Medicine Oh edn). RC Blast Jr, DW Kufe, RE Pollock et al. (Eds), BC Decker, Inc., Hamilton, Ontario, Canada (2000)625–647.
   Google Scholar
• ••Comprehensive book chapter review.
   Google Scholar
• SENDEROFF RI, WEBER PA, SMITHDR, SOKOLOSKI TD: Evaluation of antiproliferative agents using a cell-culture model. Invest. Ophthalmol Vis. Sci (1990) 31:2572–2578.
   PubMed Web of Science ®Google Scholar
• KEMENY NE, FONG Y: Treatment of liver metastases. In: Holland-Frei Cancer Medicine, (5" edn). RC Blast Jr, DW Kufe, RE Pollock et al. (Eds), BC Decker, Inc., Hamilton, Ontario, Canada (2000):1402–1414.
   Google Scholar
• MARGOLESE RG, FISHER B, HORTOBAGYI GN, BLOOMER WD: Neoplasms of the breast. In: Holland-Frei Cancer Medicine, (5" edn). RC Blast Jr, DW Kufe, RE Pollock et al. (Eds). BC Decker, Inc., Hamilton, Ontario, Canada (2000):1735–1822.
   Google Scholar
• DAVIES MM, JOHNSTON PG, KAUR S, ALLEN-MERSH TG: Colorectal liver metastasis thymidylate synthase staining correlates with response to hepatic arterial floxuridine. Clin. Cancer Res. (1999) 5:325–328.
   PubMed Web of Science ®Google Scholar
• PLANTE LT, CRAWFORD EJ, FRIEDKIN M: Enzyme studies with new analogues of folic acid and homofolic acid. Biol. Chem. (1967) 242:1466–1476.
   Web of Science ®Google Scholar
• SIROTNAK FM, DEGRAW JL, SCHMID FA, GOUTAS LJ, MOCCIO DM: New folate analogues of the 10-deaza-aminopterin series. Further evidence for markedly increased antitumor efficacy compared with methotrexate in ascitic and solid murine tumor models. Cancer Chemother. Pharmacol (1984) 12:26–30.
   Google Scholar
• FRY DW, JACKSON RC: Biological andbiochemical properties of new anticancer folate antagonists. Cancer Metastasis Rev (1987) 5:251–270.
   PubMed Web of Science ®Google Scholar
• ITOH F, RUSSELLO 0, AKIMOTO H, BEARDSLEY GP: Novel pyrrolo [2,3-dlpyrimidine antifolate TNP-351: cytotoxic effect on methotrexate-resistant CCRF-CEM cells and inhibition of transformylases of de novo purine biosynthesis. Cancer Chemother. Pharmacol (1994) 34:273–279.
   PubMed Web of Science ®Google Scholar
• ROUGIER P, PAILLOT B, LAPLANCHE A et al.: 5-Fluorouracil (5-FU) continuous intravenous infusion compared with bolus administration. Final results of a randomised trial in metastatic colorectal cancer. Ear J. Cancer (1997) 33:1789–1793.
   Google Scholar
• CASSATA A, PROCOPLO G, ALU M et al.: Capecitabine: indications and future perspectives in the treatment of metastatic colorectal and breast cancer. 7ilmori (2001) 87:364–371.
   Google Scholar
• KEYOMARSI K, SAMET J, MOLNAR G, PARDEE AB: The thymidylate synthase inhibitor ICI D1694 overcomes translational detainment of the enzyme. Biol. Chem. (1993) 268:15132–15149.
   Google Scholar
• ••Important study demonstrating post-transcriptional modulation of TS induced by an antifolate.
   Google Scholar
• PETERS GJ, BACKUS HH, FREEMANTLE S et al: Induction of thymidylate synthase as a 5-fluorouracil resistance mechanism. Biochim. Biophys. Acta (2002) 1587:194–205.
   PubMed Web of Science ®Google Scholar
• LACKEY DB, GROZIAK MP, SERGEEVA M et al.: Enzyme-catalyzed therapeutic agent (ECTA) design: activation of the antitumor ECTA compound NB1011 by thymidylate synthase. Biochem. Pharmacol (2001) 61:179–189.
   PubMed Web of Science ®Google Scholar
• LI Q, BOYER C, LEE JY, SHEPARD HM: A novel approach to thymidylate synthase as a target for cancer chemotherapy. Ma Pharmacol (2001) 59:446–452.
   PubMed Web of Science ®Google Scholar
• JONES TR, CALVERT AH, JACKMAN AL, BROWN SJ, JONES M, HARRAP KR.: A potent antitumour quinazoline inhibitor of thymidylate synthetase: synthesis, biological properties and therapeutic results in mice. Ear. Cancer (1981) 17:11–19.
   Google Scholar
• CAL VERT AH, ALISON DL, HARLAND SJ et al: A Phase I evaluation of the quinazoline antifolate thymidylate synthase inhibitor, N10-propargy1-5, 8-dideazafolic acid, CB 3717. Gin. Oncol (1986) 4:1245–1252.
   Web of Science ®Google Scholar
• MARSHAM PR, HUGHES LR, JACKMAN AL et al.: Quinazoline antifolate thymidylate synthase inhibitors: heterocyclic benzoyl ring modifications. Med. Chem. (1991) 34:1594–1605.
   Web of Science ®Google Scholar
• JACKMAN AL, TAYLOR GA, GIBSON W et al: ICI D1694, a quinazoline antifolate thymidylate synthesis inhibitor that is a potent inihibitor of L1210 tumor cell growth M vitro and in vivo: a new agent for clinical study. Cancer Res. (1991) 51:5579–5586.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, FARRUGIA DC, GIBSON W et al: ZD1694 (Tomudex): A new thymidylate synthase inhibitor with activity in colorectal cancer. Ear. Cancer (1995) 31A:1277–1282.
   PubMed Web of Science ®Google Scholar
• SPINELLA MJ, BRIGLE KE, SIERRA EE,GOLDMAN ID: Distinguishing between folate receptor-alpha-mediated transport and reduced folate carrier-mediated transport in L1210 leukemia cells. Biol. Chem. (1995) 270:7842–7849.
   Web of Science ®Google Scholar
• WESTERHOF GR, JANSEN G, VAN EMMERIK N et al.: Membrane transport of natural folates and antifolate compounds in murine L1210 leukemia cells: role of carrier- and receptor-mediated transport systems. Cancer Res. (1991) 51:5507–5513.
   Google Scholar
• ANDERSON RGW, KAMEN BA, ROTHBERG KG, LACEY SW: Potoeytosis: sequestration and transport of small molecules by caveolae. Science (1992) 255:410–411.
   PubMed Web of Science ®Google Scholar
• VVESTERHOF GR, SCHORNAGEL JH,KATHMANN I et al.: Carrier- andreceptor-mediated transport of folate antagonists targeting folate-dependent enzymes: correlates of molecular-structure and biological activity. MM. Pharmacol (1995) 48:459–471.
   Google Scholar
• CUNNINGHAM D, ZALCBERG JR, PATH U et al: `Tomudex' (ZD1694): results of a randomised trial in advanced colorectal cancer demonstrate efficacy and reduced mucositis and leucopenia. The `Tomudex' Colorectal Cancer Study Group. Ear J. Cancer (1995) 31A:1945–1954.
   PubMed Web of Science ®Google Scholar
• KERR D, CUNNINGHAM D, ZALCBERG J et al.: `Tomudex' (ZD1694) has superior response rate and toxicity profiles compared to 5-fluorouracil and leucovorin (5-FU-LV) in advanced colorectal cancer (CRC): first results of a large international Phase III study. Br. Cancer (1995) 72 (Suppl. 25):10.
   Google Scholar
• CUNNINGHAM D, ZALCBERG JR, PATH U: Final results of a randomised trial comparing `Tomudex'.. (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. Ann. Oncol (1996) 7:96–1965.
   Google Scholar
• MAUGHAN TS, JAMES RD, KERR DJ et al.: Comparison of survival, palliation, and quality of life with three chemotherapy regimens in metastatic colorectal cancer: a multicentre randomized trial. Lancet (2002) 359:1555–1563.
   PubMed Web of Science ®Google Scholar
• SMITH I, JONES A, SPIELMANN M et al.: A Phase II study in advanced breast cancer: ZD1694 ('Tomudex') a novel direct and specific thymidylate synthase inhibitor. Br. Cancer (1996) 74:479–481.
   Google Scholar
• BURRIS H, VON HOFF D, BOWEN K et al.: A Phase II trial of ZD1694, a novel thymidylate synthase inhibitor, in patients with advanced non-small cell lung cancer. Annals. Oncol (1994), 5(Supp. 5):133 (Abstract 244).
   Google Scholar
• PAZDUR R, MEROPOL NJ, CASPER ES et al: Phase II trial of ZD1694 (tomudex) in patients with advanced pancreatic cancer. Invest. New Drugs (1996) 13:355–358.
   PubMed Web of Science ®Google Scholar
• DE JONG MJ, PUNT CJ, SPARREBOOM A: Phase I and pharmacologic study of oral ZD9331, a novel nonpolyglutamated thymidylate synthase inhibitor, in adult patients with solid tumors.Oncol (2002)20: 1923-1931.
   Google Scholar
• JACKMAN AL, MELIN CJ, KIMBELL R et al.: A rationale for the clinical development of the thymidylate synthase inhibitor ZD9331 in ovarian and other solid tumours. Biochim. Biophys. Acta (2002) 1587:215–223.
   PubMed Web of Science ®Google Scholar
• JACKMAN AL, CALVERT AH: Folate-based thymidylate synthase inhibitors as anticancer drugs. Ann. Oncol (1995) 6:871–881.
   PubMed Web of Science ®Google Scholar
• O'DWYER PJ, LAUB PB, DeMARIA D et al.: Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion. Clio. Cancer Res. (1996) 2:1685–1692.
   Google Scholar
• CREAVEN PJ, PENDYALA L, MEROPOL NJ et al.: Initial clinical trial and pharmacokinetics of ThymitaqTM (AG337) by 10-day continuous infusion in patients with advanced solid tumors. Cancer Chemother. Pharmacol (1998) 41:167–170.
   PubMed Web of Science ®Google Scholar
• ROSELL R, CRINO L: Pemetrexed continuation therapy in the treatment of non-small cell lung carcinoma. Semin. Oncol (2002) 29(2, Suppl. 5):23–29.
   Google Scholar
• FIZAZI K, JOHN WJ, VOGELZANG NJ: The emerging role of antifolates in the treatment of malignant pleural mesothelioma. Serino. Oncol (2002) 29:77–81.
   PubMed Web of Science ®Google Scholar
• DANENBERG PV, MALLI H, SWENSON S: Thymidylate synthase inhibitors. Semin. Oncol (1999) 26:621–631.
   PubMed Web of Science ®Google Scholar
• •Review.
   Google Scholar
• TOUROUTOGLOU N, PAZDUR R: Thymidylate synthase inhibitors. Clio. Cancer Res. (1996) 2:227–243.
   PubMed Web of Science ®Google Scholar
• •Review.
   Google Scholar
• CAPIZZI RL, DECONTI RC, MARSH JC, BERTINO JR: Methotrexate therapy of head and neck cancer: improvement in therapeutic index by the use of leucovorin 'rescue'. Cancer Res. (1970) 30:1782–1788.
   PubMed Web of Science ®Google Scholar
• EVANS RM, LASKIN JD, HAKALA MT:Effects of excess folates and deoxyinosine on the activity and site of action of 5-fluorouracil. Cancer Res. (1981) 41:3288–3295.
   PubMed Web of Science ®Google Scholar
• FERNANDES DJ, BERTINO JR: 5-Fluorouracil-methotrexate synergy: enhancement of 5-fluorodeoxyuridylate binding to thymidylate synthase by dihydropteroylpolyglutamates. Proc. Nat. Acad. Sci. USA (1980) 77:5663–5667.
   PubMed Web of Science ®Google Scholar
• JODRELL DI, OSTER W, KERR DJ et al.: A Phase I-II study of N-(phosphonacety1)-L-aspartic acid (PALA) added to 5-fluorouracil and folinic acid in advanced colorectal cancer. Ear. J. Cancer (1994) 30A:950–955.
   PubMed Web of Science ®Google Scholar
• GREM JL, VAN GROENINGEN CJ, ISMAIL AA, JOHNSTON PG, ALEXANDER HR, ALLEGRA CJ: The role of interferon-a as a modulator of fluorouracil and leucovorin. Ear. J. Cancer (1995) 31A:1316–1320.
   PubMed Web of Science ®Google Scholar
• PORTER DJ, CHESTNUT WG, MERRILL BM, SPECTOR T: Mechansim-based inactivation of dihydropyridine dehydrogenase by ethyluracil (776C85). Biol. Chem. (1992) 267:5236–5242.
   Web of Science ®Google Scholar
• LEHMAN NL, DANENBERG PV: Modulation of RTX cytotoxicity by thymidine and dipyridamole M vitro: implications for chemotherapy. Cancer Chemother. Pharmacol (2000) 45:142–148.
   PubMed Web of Science ®Google Scholar
• ••Study showing potentiation of raltitrexedactivity by dipyridamole under physiological thymidine concentrations.
   Google Scholar
• WEBER G: Biochemical strategy of cancer cells and the design of chemotherapy; G. H. A. Clowes Memorial Lecture. Cancer Res. (1983) 43:3466–3492.
   PubMed Web of Science ®Google Scholar
• DENTON JE, LUI MS, AOKI T et al.: Enzymology of pyrimidine and carbohydrate metabolism in human colon carcinomas. Cancer Res. (1982) 42:1176–1183.
   PubMed Web of Science ®Google Scholar
• NATSUMEDA Y, PRAJDA N, DONOHUE JP, GLOVER JL, WEBER G: Enzymatic capacities of purine de novo and salvage pathways for nucleotide synthesis in normal and neoplastic tissues. Cancer Res. (1984) 44:2475–2479.
   PubMed Web of Science ®Google Scholar
• NATSUMEDA Y, LUI MS, EMRANI J et al.: Purine enzymology of human colon carcinomas. Cancer Res. (1985) 45:2556–2559.
   PubMed Web of Science ®Google Scholar
• ZHEN YS, TANIKI T, WEBER G: Azidothymidine and dipyridamole as biochemical modifiers: synergism with methotrexate and 5-fluorouracil in human colon and pancreatic carcinoma cells. Oncology Res. (1992) 4:73–78.
   PubMed Web of Science ®Google Scholar
• PRESSACCO J, ERLICHMAN C: Combination studies with 3'-azido-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects. Biochem. Pharmacol (1993) 46:1989–1997.
   PubMed Web of Science ®Google Scholar
• GREM JL, FISCHER PH: Augmentation of 5-fluorouracil cytotoxicity in human colon cancer cells by dipyridamole. Cancer Res. (1985) 45:2967–2972.
   PubMed Web of Science ®Google Scholar
• CURTIN NJ, HARRIS AL: Potentiation of quinazoline antifolate (CB3717) toxicity by dipyridamole in human lung carcinoma, A549, cells. Biochem. Pharmacol (1988) 37:2113–2120.
   PubMed Web of Science ®Google Scholar
• CHAN TCK, HOWELL SB: Mechanism of synergy between N-phosphon-acetyl-L-aspartate and dipyridamole in a human ovarian carcinoma cell line. Cancer Res. (1985) 45:3598–3604.
   PubMed Web of Science ®Google Scholar
• JEKUNEN A, VICK J, SANGA R, CHAN TC, HOWELL SB: Synergism between dipyridamole and cisplatin in human ovarian carcinoma cells in vitro. Cancer Res. (1992) 52:3566–3571.
   PubMed Web of Science ®Google Scholar
• KUSUMOTO H, MAEHARA Y, ANAI H, KUSUMOTO T, SUGIMACHI K: Potentiation of adriamycin cytotoxicity by dipyridamole against HeLa cells in vitro and sarcoma 180 cells in vivo. Cancer Res. (1988) 48:1208–1212.
   PubMed Web of Science ®Google Scholar
• TURNER RN, CURTIN NJ: Dipyridamole increases VP16 growth inihibition, accumulation and retention in parental and multidrug-resistant CHO cells. Br. J. Cancer (1996) 73:856–860.
   PubMed Web of Science ®Google Scholar
• MUGGIA FM, SLOWIACZEK P, TATTERSALL MHN: Characterization of conditions in which dipyridamole enhances methotrexate toxicity in L1210 cells. Anticancer Res. (1987) 7:161–166.
   PubMed Web of Science ®Google Scholar
• ASOH KI, SABURI Y, SATO SI, NOGAE I, KOHNO K, KUWANO M: Potentiation of some anticancer agents by dipyridamole against drug-sensitive and drug-resistant cancer cell lines. fpn. J. Cancer Res. (1989) 80:475–481.
   PubMedGoogle Scholar
• HOLDEN L, HOFFBRAND AV, TATTERSALL MHN: Thymidine concentrations in human sera: variations in patients with leukemia and megaloblastic anemia. Eur. J. Cancer (1980) 16:115–121.
   PubMed Web of Science ®Google Scholar
• HOWELL SB, MANSFIELD SJ, TAETLE R: Significance of variation in serum thymidine concentration for the marrow toxicity of methotrexate. Cancer Chemother: Pharmacol (1981) 5:221–226.
   PubMed Web of Science ®Google Scholar
• GREM JL: Biochemical modulation of fluorouracil by dipyridamole: preclinical and clinical experience. Semin. Oncol (1992) 19(2, Suppl. 3):56–65.
   Google Scholar
• KOHNE CH, HIDDEMANN W, SCHULLER J et al.: Failure of orally administered dipyridamole to enhance the antineoplastic activity of fluorouracil in combination with leucovorin in patients with advanced colorectal cancer: a prospective randomized trial." Clio. Oncol (1995) 13:1201–1208.
   Google Scholar
• ••
   Google Scholar
• BURCH PA, GHOSH C, SCHROEDER G et al.: Phase II evaluation of continuous-infusion 5-fluorouracil, leucovorin, mitomycin-C, and oral dipyridamole in advanced measurable pancreatic cancer: a North Central Cancer Treatment Group Trial. Am. I Clin. Oncol (2000) 23:534–537.
   PubMed Web of Science ®Google Scholar
• NOMURA M, NAKANO S, KUDOU J, ISHIBASHI 0, NIHO Y: Successful treatment of advanced gastric cancer with multiple liver metastasis by combination chemotherapy using mitomycin C, 5-fluorouracil, and high-dose leucovorin: a case report. fpn. Cancer Chemother. (1990) 17:2097–2100.
   PubMedGoogle Scholar
• MITSUGI K, YASUTAKE T, ETOH T et al.: Successful treatment of recurrent multiple lung metastasis from colon cancer with combination chemotherapy using methotrexate, 5-fluorouracil, and high-dose leucovorin: a case report. fpn. Cancer Chemother. (1993) 20:2387–2390.
   PubMedGoogle Scholar
• SUGIMORI H, NAKANO S, CHIFU Y et al.: 5-Fluorouracil + low-dose leucovorin and cisplatin sequential chemotherapy with dipyridamole for advanced nonresectable squamous cell carcinoma of the lung: a case report. fpn. Cancer Chemother. (1993) 20:287–290.
   PubMedGoogle Scholar
• CHAKRAVARTHY A, ABRAMS RA, YEO CJ et al.: Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int. .1 Radiat. Oncol Biol. Phys. (2000) 48:1089–1096.
   Google Scholar
• TODD KE, GLOOR B, LANE JS, ISACOFF WH, REBER HA: Resection of locally advanced pancreatic cancer after downstaging with continuous-infusion 5-fluorouracil, mitomycin-C, leucovorin, and clipyridamole.J Castrointest. Surg. (1998) 2:159–166.
   PubMedGoogle Scholar
• CHEN HX, BAMBERGER U, HECKEL A, GUO X, CHENG YC: BIBW 22, a dipyridamole analogue, acts a bifunctional modulator on tumor cells by influencing both P-glycoprotein and nucleotide transport. Cancer Res. (1993) 53:1974–1977.
   PubMed Web of Science ®Google Scholar
• JANSEN WJ, PINEDO HM, KUIPER CM et al: Biochemical modulation of 'classical' multidrug resistance by BIBW22BS, a potent derivative of dipyridamole. Ann. Oncology (1994) 5:733–739.
   PubMed Web of Science ®Google Scholar
• GOEL R, CLEARY SM, HORTON C et al.: Selective intraperitoneal biochemical modulation of methotrexate by dipyridamole. .1 Clin. Oncol (1989) 7:262–269.
   Google Scholar
• PRESSACCO J, MITROVSKI B, ERLICHMAN C, HEDLEY DW: Effects of thymidylate synthase inhibition on thymidine kinase activity and nucleoside transporter expression. Cancer Res. (1995) 55:1505–1508.
   PubMed Web of Science ®Google Scholar
• BOYER CR, KARJIAN PL, WAHL GM, PEGRAM M, NEUTEBOOM ST: Nucleoside transport inhibitors, dipyridamole and p-nitrobenzylthioinosine, selectively potentiate the antitumor activity of NB1011. Anti-Cancer Drugs (2002) 13:29–36.
   PubMed Web of Science ®Google Scholar
• HORIKOSHI T, DANENBERG KD, STADLBAUER THW et al.: Quantitation of thymidylate synthase, dihydrofolate reductase, and DT-diaphorase gene expression in human tumors using the polymerase chain reaction. Cancer Res. (1991) 52:108–116.
   Web of Science ®Google Scholar
• •Study demonstrating quantitation of TS mRNA levels in small gastrointestinal biopsies by RT-PCR.
   Google Scholar
• JOHNSTON P G, LENZ HJ, DANENBERG KD et al.: Thymidylate synthase gene and protein expression correlate and are associated with response to 5-fluorouracil in human colorectal and gastric tumors. Cancer Res. (1995) 55:1407–1412.
   PubMed Web of Science ®Google Scholar
• ••Important early pharmacogenetic studyshowing clinical response to fluororouracil correlates with tumour TS mRNA and protein levels.
   Google Scholar
• LENZ HJ, LEICHMAN CG, DANENBERG KD et al.: Thymidylate synthase mRNA level in adenocarcinoma of the stomach: a predictor for primary tumor response and overall survival. Clin. Oncol (1996) 14:176–182.
   Web of Science ®Google Scholar
• LINK KH, KORNMANN M, BUTZERU et al.: Thymidylate synthase quantitation and in vitro chemosensitivity testing predicts responses and survival of patients with isolated nonresectable liver tumors receiving hepatic arterial infusion chemotherapy. Cancer (2000) 89:288–296.
   PubMed Web of Science ®Google Scholar
• SALONGA D, DANENBERG KD, JOHNSON M et al.: Colorectal tumors responding to 5-fluorouracil have low gene expression levels of dihydropyrimidine dehydrogenase, thymidylate synthase, and thymidine phosphorylase. Clin. Cancer Res. (2000) 6:1322–1327.
   PubMed Web of Science ®Google Scholar
• METZGER R, DANENBERG K, LEICHMAN CG et al.: High basal level gene expression of thymidine phosphorylase (platelet-derived endothelial cell growth factor) in colorectal tumors is associated with nonresponse to 5-fluorouracil. Clin. Cancer Res. (1998) 4:2371–2376.
   PubMed Web of Science ®Google Scholar
• DRAKE JC, ALLEGRA CJ, MORAN RG, JOHNSTON PG: Resistance to Tomudex (ZD1694): multifactoral in human breast and colon carcinoma cell lines. Biochem. Pharmacol (1996) 51:1349–1355.
   PubMed Web of Science ®Google Scholar
• ROTHEM L, IFERGAN I, KAUFMAN Y, PRIEST DG, JANSEN G, ASSARA F: Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukemia cell lines. Biochem. .1 (2002) 367:741–750.
   PubMed Web of Science ®Google Scholar
• RHEE MS, WANG Y, NAIR MG, GALIVAN J: Acquisition of resistance to antifolates caused by enhanced gamma-glutamyl hydrolase activity. Cancer Res. (1993) 53:2227–2230.
   PubMed Web of Science ®Google Scholar
• LI WW, WALTHAM M,TONGW, SCHWEITZER BI, BERTINO JR: Increased activity of gamma-glutamyl hydrolase in human sarcoma cell lines: a novel mechanism of intrinsic resistance to methotrexate (MTX). Adv. Exp. Med. Biol. (1993) 338:635–638.
   PubMedGoogle Scholar
• MINI E, BIONDI C, MORGANTI M et al.: Marked variation of thymidylate synthase and folylpolyglutamate synthetase gene expression in human colorectal tumors. Oncol Res. (1999) 11:437–445.
   PubMed Web of Science ®Google Scholar
• MIOTTI S, CANEVARI S, MENARD S et al.: Characterization of human ovarian carcinoma-associated antigens defined by novel monoclonal antibodies with tumor-restricted specificity. Int. .1 Cancer (1987) 39:297–303.
   Google Scholar
• BUENO R, APPASANI K, MERCER H, LESTER S, SUGARBAKER D: The alpha folate receptor is highly activated in malignant pleural mesothelioma. Thome. Cardiovasc. Surg. (2001) 121:225–233.
   Web of Science ®Google Scholar
• VVEITMAN SD, LARK RH, CONEY LR et al.: Distribution of the folate receptor GP38 in normal and malignant cell lines and tissues. Cancer Res. (1992) 52:3396–3401.
   PubMed Web of Science ®Google Scholar
• SCHENA M, SHALON D, DAVIS RW, BROWN PO: Quantitative monitoring of gene expression patterns with a complementary DNA microarray. Science (1995) 270:467–470.
   Google Scholar
• ••Paper describing cDNA microaiTaytechnology.
   Google Scholar
• CARTWRIGHT CP: Pharmacogenetics: the Dx perspective. Expert. Rev Mol Diagn. (2001) 1:371–376.
   PubMedGoogle Scholar
• O'DWYER ME, DRUKER BJ: The role of the tyrosine kinase inhibitor STI571 in the treatment of Cancer. Curt: Cancer Drug Targets (2001) 1:49–57.
   PubMed Web of Science ®Google Scholar
• HARRIES M, SMITH I: The development and clinical use of trastuzumab (Herceptin). Endocr. Relat. Cancer (2002) 9:75–85.
   PubMed Web of Science ®Google Scholar
• CHESON BD: Hematologic malignancies: new developments and future treatments. Semin. Oncol (2002) 29(4, Suppl. 13): 33–45.
   Google Scholar
• FONTANA JA, RISHI AK: Classical and novel retinoids: their targets in cancer therapy. Leukemia (2002) 16:463–472.
   PubMed Web of Science ®Google Scholar
• ELLIOT PJ, ROSS JS: The proteosome: a new target for novel drug therapies. Am. J. Clin. PathoL (2001) 116:637–646.
   PubMed Web of Science ®Google Scholar